Genmab A GMAB
NASDAQ GMAB
$54.07 -1.74 (-3.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Genmab A (GMAB) Net Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported Net Margin of 21.30% for the quarter ended Jun 30, 2026, up 33.13 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) Net Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's Net Margin came in at 22.16%; for the year ended Dec 31, 2025, it came in at 27.10%, down 2.03 percentage points from the prior year.

  • By year, Net Margin came in at 29.13% in the year ended Dec 31, 2024 (-3.09 pp) and 32.22% in the year ended Dec 31, 2023.
  • Five-year quarterly Net Margin spans a low of -11.83% in the quarter ended Mar 31, 2026 and a high of 45.29% in the quarter ended Sep 30, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 0.83%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 24.24%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 28.01%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 22.65%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 16.30%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 37.28%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 29.27%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 19.55%
10 Genmab A 3.52 Bn -5.55 Bn 1.07 Bn 26.23%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 27.38%
Jun 30, 2026 21.30%
Mar 31, 2026 -11.83%
Sep 30, 2025 39.82%
Jun 30, 2025 36.65%
Mar 31, 2025 29.09%
Sep 30, 2024 38.60%
Jun 30, 2024 22.21%
Mar 31, 2024 33.00%
Sep 30, 2023 45.29%
API Access

Genmab A Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY